Takahiro Mizutani

No ORCID on file · 5 papers in corpus
case-report 1999
American journal of obstetrics and gynecology ·doi:10.1016/s0002-9378(99)70523-5

A gonadotropin-releasing hormone agonist, leuprolide acetate, was administered every 4 weeks for treatment of rectovaginal endometriosis. Degrees of apoptosis (percentage of in situ deoxyribonucleic acid 3'-end-labeled cells) and cell proli…

nonrandomized-trial 1995
Fertility and sterility ·doi:10.1016/s0015-0282(16)57594-3

OBJECTIVE: To determine danazol concentrations in the ovary, uterus, and serum during daily vaginal administration of a danazol suppository and to examine its effect on the hypothalamic-pituitary-ovarian axis. DESIGN: Sampling of tissues a…

lab-animal 1990
American journal of obstetrics and gynecology ·doi:10.1016/0002-9378(90)90650-v

Effects of danazol, gonadotropin-releasing hormone agonist (leuprolide), and danazol-leuprolide combination on experimental endometriosis were evaluated in female rats. A complete resorption of the fluid and a marked decrease in the volume …

nonrandomized-trial 1989
Endocrinologia japonica ·doi:10.1507/endocrj1954.36.611

The chronic administration of GnRH agonists to women results in the reversible suppression of estrogen production by the ovary. In the present study, the mechanism of the GnRH agonist suppression of estrogen production was investigated in p…

other 1988
Cancer ·doi:10.1002/1097-0142(19881215)62:12<2618::aid-cncr2820621228>3.0.co;2-i

Since the authors recently reported that danazol inhibits the growth of human endometrial cancer cells in vitro, a clinical trial was initiated to examine whether danazol can regress adenomatous hyperplasia, a precursor of endometrial adeno…